AC
OTLK icon

Armistice Capital’s Outlook Therapeutics OTLK Stock Holding History

Armistice Capital’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$858K Buy
+4,168,000
New +$1.8M 0.02% 167
2024
Q2 		– Sell
-714,285
Closed -$8.53M – 350
2024
Q1 		$8.53M Buy
+714,285
New +$5.78M 0.11% 104
2020
Q2 		– Sell
-70,619
Closed -$849K – 90
2020
Q1 		$849K Buy
+70,619
New +$1.17M 0.05% 74

Other funds holding OTLK

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Armistice Capital's OTLK Position: Q1 2026 in Review

Armistice Capital opened a new position in Outlook Therapeutics (OTLK) in Q1 2026: 4,168,000 shares worth $858K. The stake represents 0.02% of the portfolio and ranks #167 among its holdings. This is a return to the name: Armistice Capital previously reported a position in OTLK as recently as Q1 2024.

Armistice Capital first reported a position in OTLK in Q1 2020 and has held it in 3 quarters since. The position peaked at $8.53M in Q1 2024. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Armistice Capital held 4,168,000 shares of Outlook Therapeutics worth $858K as of Q1 2026.
  • Outlook Therapeutics was a new Armistice Capital position in Q1 2026.
  • Outlook Therapeutics made up 0.02% of Armistice Capital's portfolio in Q1 2026, its #167 holding.
  • Armistice Capital first reported a position in Outlook Therapeutics in Q1 2020 and has held it in 3 quarters since.
  • Armistice Capital's Outlook Therapeutics position peaked at $8.53M in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.